Abstract-The present study was designed to examine whether chronic adrenomedullin infusion has renoprotective effects in hypertensive renal failure and the mechanism by which chronic adrenomedullin infusion exerts its effects. Dahl salt-sensitive rats and Dahl salt-resistant rats were fed a high salt diet starting at 6 weeks of age. Recombinant human adrenomedullin or vehicle was infused for 7 weeks in 11-week-old Dahl salt-sensitive rats. Dahl salt-resistant rat was used as a control. After 7 weeks, untreated Dahl salt-sensitive rats were characterized by decreased kidney function, abnormal morphological findings, increased hormone levels, increased renal tissue angiotensin II levels, and altered mRNA expressions of transforming growth factor  (TGF-) and components of the renin-angiotensin system compared with Dahl salt-resistant rats. Chronic adrenomedullin treatment significantly improved renal function (serum creatinine Ϫ87%, creatinine clearance ϩ114%, urinary protein excretion Ϫ59%) and histological findings (glomerular injury score Ϫ54%) without changing mean arterial pressure compared with untreated Dahl salt-sensitive rats. Interestingly, long-term human adrenomedullin infusion decreased the endogenous rat adrenomedullin level (Ϫ97%) with a slight increase of human adrenomedullin level. Chronic adrenomedullin treatment also significantly inhibited the increase of plasma renin concentration (Ϫ269%), aldosterone level (Ϫ82%), and renal tissue angiotensin II levels (Ϫ60%). Furthermore, adrenomedullin infusion significantly decreased the increases of mRNA expressions of TGF- (Ϫ63%), angiotensin-converting enzyme (Ϫ137%), renin (Ϫ230%), and angiotensinogen (Ϫ38%) in renal cortex. These results suggest that increased endogenous adrenomedullin plays a compensatory role in chronic hypertensive renal failure and that long-term adrenomedullin infusion has renoprotective effects in this type of hypertension model, partly via inhibition of the circulating and renal renin-angiotensin system. Key Words: adrenomedullin Ⅲ hypertension, experimental Ⅲ rats, Dahl Ⅲ renin-angiotensin system Ⅲ transforming growth factors A drenomedullin (AM) is a novel vasodilatory peptide originally discovered in human pheochromocytoma tissue. 1 Subsequent studies demonstrated that AM is widely distributed in the cardiovascular system, including the kidney, heart, lungs, and blood vessels. 1 AM gene transcripts and specific binding sites for this peptide are also present at high levels in the kidney, heart, lungs, and blood vessels. 2 Immunohistochemistry of AM in the canine kidney has revealed AM immunoreactivity in glomeruli, cortical distal tubules, and medullary collecting duct cells. 3 These results suggest that AM may play a role in the regulation of kidney function. Indeed, intrarenal infusion of AM increased the renal blood flow (RBF) and glomerular filtration rate (GFR) and lowdose intrarenal infusion of AM increased the urinary flow and sodium excretion without changes in GFR. 3 These effects are mediated by AM binding to a G...